MedTech Strategist has published an in-depth interview with STENTiT’s CEO Bart Sanders in their latest issue as Start-Up to Watch.
Together with Senior Writer/Market Analyst Mary Stuart they focus on the unique potential of STENTiT’s endovascular regenerative technology, while discussing the recent developments in the field as well as lessons learned from the past.
About MedTech Strategist:
MedTech Strategist, the industry’s most trusted strategic publication, was created to not just explain what is going on in the medical device space today, but why these events are occurring and what they may lead to in the future on a worldwide scale.
The global medical device industry is evolving rapidly and more change is coming. While these changes bring challenges, they also create opportunities for those in the know. Our subject-matter experts mine real-word stories, solicit outside perspectives from industry experts, and frame it in context with insight gained from our combined 150 years of medtech experience to help you turn these obstacles into opportunities.
Read the interview:
Read the full article “STENTiT: Scaffolds Regenerate Arteries From the Inside Out” on the MedTech Strategist website.